Trials / Completed
CompletedNCT05000684
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab in Patients With Advanced Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label phase I/II study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab in patients with advanced lung cancer who have failed standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JS004 in combination with toripalimab | Usage and dosage: 200mg of JS004 combined with 240mg of JS001 is given every 3 weeks |
Timeline
- Start date
- 2021-08-27
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
- First posted
- 2021-08-11
- Last updated
- 2025-02-20
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05000684. Inclusion in this directory is not an endorsement.